Baclofen for binge eating: An open‐label trial

Broft, Allegra; Spanos, Alexia; Corwin, Rebecca L.; Mayer, Laurel; Steinglass, Joanna E.; Devlin, Michael J.; Attia, Evelyn; Walsh, B. Timothy

doi:10.1002/eat.20434

Cited by 105 publications

(62 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, atomoxetine, fluoxetine, topiramate, and baclophen have demonstrated limited efficacy in clinical studies for BED (McElroy et al, 2007a,b;Broft et al, 2007;Grilo et al, 2012). The present work demonstrated that, in preclinical models, the novel NOP receptor antagonist LY2940094 effectively inhibited feeding behavior.…”

Section: Discussionmentioning

confidence: 52%

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

Statnick

Chen

Ansonoff

et al. 2015

Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

Nociceptin/orphanin FQ (N/OFQ), a 17 amino acid peptide, is the endogenous ligand of the ORL1/nociceptin-opioid-peptide (NOP) receptor. N/OFQ appears to regulate a variety of physiologic functions including stimulating feeding behavior. Recently, a new class of thienospiro-piperidine-based NOP antagonists was described. One of these molecules, LY2940094 has been identified as a potent and selective NOP antagonist that exhibited activity in the central nervous system. Herein, we examined the effects of LY2940094 on feeding in a variety of behavioral models. Fasting-induced feeding was inhibited by LY2940094 in mice, an effect that was absent in NOP receptor knockout mice. Moreover, NOP receptor knockout mice exhibited a baseline phenotype of reduced fasting-induced feeding, relative to wild-type littermate controls. In lean rats, LY2940094 inhibited the overconsumption of a palatable high-energy diet, reducing caloric intake to control chow levels. In dietary-induced obese rats, LY2940094 inhibited feeding and body weight regain induced by a 30% daily caloric restriction. Last, in dietary-induced obese mice, LY2940094 decreased 24-hour intake of a high-energy diet made freely available. These are the first data demonstrating that a systemically administered NOP receptor antagonist can reduce feeding behavior and body weight in rodents. Moreover, the hypophagic effect of LY2940094 is NOP receptor dependent and not due to off-target or aversive effects. Thus, LY2940094 may be useful in treating disorders of appetitive behavior such as binge eating disorder, food choice, and overeating, which lead to obesity and its associated medical complications and morbidity.

show abstract

Section: Discussionmentioning

confidence: 52%

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

Statnick

Chen

Ansonoff

et al. 2015

Journal of Pharmacology and Experimental Therapeutics

View full text Add to dashboard Cite

show abstract

“…Recent studies also reported that baclofen was effective to treat binge-eating of fat in animals (14) as well as binge-eating in humans (15), the mechanisms of which have been postulated to be similar to drug abuse (14). While we have not examined changes in the desire for fat exclusively, the desire to take sweets evaluated by a visual analogue scale was decreased by baclofen in this study.…”

Section: Discussionmentioning

confidence: 53%

Positive Effect of Baclofen on Body Weight Reduction in Obese Subjects: A Pilot Study

Arima

Oiso

2010

Intern. Med.

View full text Add to dashboard Cite

Background and objective We previously reported that baclofen, a GABAB agonist, reduces body weight in obese mice. In this clinical study, we examined the possibility that baclofen might serve as an effective therapeutic agent for obesity in humans. Methods Seven women and three men ranging from 25-51 years of age and 31.3-41.0 kg/m 2 body mass index were included in the study. Baclofen, which was started at a dose of 15 mg/day and increased to 30 mg/ day in 10 days, was administered for 12 weeks. Results Administration of baclofen for 12 weeks significantly decreased both body weight (baseline: 93.30 ± 9.80 kg, 12 weeks: 91.70 ± 10.30 kg) and waist circumference (baseline: 107.9 ± 9.0 cm, 12 weeks: 105.6 ± 10.0 cm). Serum leptin levels, which possibly reflect the amount of adipose stores, were also decreased significantly by the treatment. On the other hand, there were no significant changes in the blood pressure or metabolism of glucose and lipid. No adverse effects were observed. Conclusion Although the anti-obesity effects of baclofen in the present study were mild, this pilot study suggests the possibility that baclofen might serve as a new anti-obesity drug in humans.

show abstract

“…[36][37][38][39][40] Preclinical, phenomenologic, and comorbidity data suggest binge eating disorder and substance use disorders are related 2,41,42 and growing research shows that medications that reduce craving and consumption of drugs of abuse 43 may also reduce binge eating. 8,9,15,44,45 Indeed, one such drug, baclofen, shares a common mechanism with sodium oxybate-agonism of centrally active GABA-B receptors. 45 Finally, sodium oxybate is well tolerated when taken as prescribed.…”

Section: Introductionmentioning

confidence: 99%

“…8,9,15,44,45 Indeed, one such drug, baclofen, shares a common mechanism with sodium oxybate-agonism of centrally active GABA-B receptors. 45 Finally, sodium oxybate is well tolerated when taken as prescribed. 16,17,24 Compared with the antidepressants, antiepileptics, and antiobesity agents presently used in binge eating disorder, sodium oxybate is associated with lower rates of sexual dysfunction, cognitive impairment, and hypertension, respectively.…”

Section: Introductionmentioning

confidence: 99%

Sodium oxybate in the treatment of binge eating disorder: An open‐label, prospective study

McElroy

Guerdjikova

Winstanley

et al. 2011

Intl J Eating Disorders

View full text Add to dashboard Cite

show abstract

Baclofen for binge eating: An open‐label trial

Abstract: In this open-label trial, baclofen was associated with decreased binge eating frequency in patients with BED and BN.

Cited by 105 publications

References 36 publications

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

Positive Effect of Baclofen on Body Weight Reduction in Obese Subjects: A Pilot Study

Sodium oxybate in the treatment of binge eating disorder: An open‐label, prospective study

Contact Info

Product

Resources

About